rofecoxib has been researched along with Acute Confusional Senile Dementia in 26 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the effectiveness and adverse effects of aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) for the primary or secondary prevention of dementia." | 9.05 | Aspirin and other non-steroidal anti-inflammatory drugs for the prevention of dementia. ( Devane, D; Jordan, F; Kelly, JP; McGuinness, B; Murphy, K; Passmore, P; Quinn, TJ; Tudur Smith, C, 2020) |
| "Using an intention-to-treat analysis of adjudicated CVT deaths, we analyzed detailed patient-level data collected during 3 randomized placebo-controlled trials of rofecoxib versus placebo that had been designed to define the drug's possible role in the prevention or treatment of Alzheimer disease." | 7.78 | Under-reporting of cardiovascular events in the rofecoxib Alzheimer disease studies. ( Avorn, J; Furberg, CD; Madigan, D; Mayer, JW; Sigelman, DW, 2012) |
| " We summarize how the sponsor represented mortality findings associated with rofecoxib in clinical trials of patients with Alzheimer disease or cognitive impairment." | 7.74 | Reporting mortality findings in trials of rofecoxib for Alzheimer disease or cognitive impairment: a case study based on documents from rofecoxib litigation. ( Kronmal, RA; Psaty, BM, 2008) |
| "To evaluate the effectiveness and adverse effects of aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) for the primary or secondary prevention of dementia." | 5.05 | Aspirin and other non-steroidal anti-inflammatory drugs for the prevention of dementia. ( Devane, D; Jordan, F; Kelly, JP; McGuinness, B; Murphy, K; Passmore, P; Quinn, TJ; Tudur Smith, C, 2020) |
| "Using an intention-to-treat analysis of adjudicated CVT deaths, we analyzed detailed patient-level data collected during 3 randomized placebo-controlled trials of rofecoxib versus placebo that had been designed to define the drug's possible role in the prevention or treatment of Alzheimer disease." | 3.78 | Under-reporting of cardiovascular events in the rofecoxib Alzheimer disease studies. ( Avorn, J; Furberg, CD; Madigan, D; Mayer, JW; Sigelman, DW, 2012) |
| "During the review process of the Vioxx Gastrointestinal Outcomes Research study, it was suggested that rofecoxib might have little benefit, with regard to GI toxicity, for patients with rheumatoid arthritis not treated with corticosteroids." | 3.77 | Rofecoxib and clinically significant upper and lower gastrointestinal events revisited based on documents from recent litigation. ( Chan, FK; Graham, DY; Jewell, NP, 2011) |
| " We summarize how the sponsor represented mortality findings associated with rofecoxib in clinical trials of patients with Alzheimer disease or cognitive impairment." | 3.74 | Reporting mortality findings in trials of rofecoxib for Alzheimer disease or cognitive impairment: a case study based on documents from rofecoxib litigation. ( Kronmal, RA; Psaty, BM, 2008) |
| "Forty two had progressed to Alzheimer type dementia during a five year follow up period and were considered to have predementia Alzheimer's disease at baseline." | 2.71 | Do MCI criteria in drug trials accurately identify subjects with predementia Alzheimer's disease? ( Scheltens, P; Verhey, FR; Visser, PJ, 2005) |
| " In the VIGOR gastrointestinal outcomes trial of >8000 patients, naproxen (an NSAID with aspirin-like sustained antiplatelet effects throughout its dosing interval) was associated with a significantly lower risk of CV events than was rofecoxib." | 2.42 | Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program. ( Gertz, BJ; Reicin, A; Sperling, RS; Weir, MR, 2003) |
| "Among the most widely prescribed drugs worldwide, non-steroidal anti-inflammatory drugs (NSAIDs) are effective for relieving pain, but they are also associated with a high incidence of gastrointestinal (GI) adverse events." | 2.41 | Do selective cyclo-oxygenase inhibitors eliminate the adverse events associated with nonsteroidal anti-inflammatory drug therapy? ( Devière, J, 2002) |
| " RATIONALE FOR THE USE OF SELECTIVE COX-2 INHIBITORS: The rationale for the prescription of selective COX-2 inhibitors as neuroprotective drugs in AD lies on: Epidemiological data having shown a reduced risk of developing AD in patients treated with anti-inflammatory doses of classical NSAIDs (inhibition of COX-1 and COX-2) but not with antithrombotic doses of aspirin (selective inhibition of COX-1), Cellular experiments, Demonstration of a better gastro-intestinal (GI) safety profile with selective COX-2 inhibitors than with classical NSAIDs in short-term studies, allowing a possible long-term use in AD." | 2.41 | [Non-steroidal anti-inflammatory drugs with selectivity for cyclooxygenase-2 in Alzheimer's disease. Rationale and perspectives]. ( Blain, A; Blain, H; Jeandel, C; Jouzeau, JY; Netter, P; Terlain, B; Touchon, J; Tréchot, P, 2000) |
| " Moreover, some epidemiologic and pilot clinical studies have proven that long-term administration of anti-inflammatory drugs have a protective effect on the onset of AD." | 2.41 | Alzheimer's disease, inflammation and non-steroidal anti-inflammatory drugs. ( Ferencik, M; Novak, M; Rovensky, J; Rybar, I, 2001) |
| " Comparisons were made between patients taking rofecoxib and those taking either placebo, naproxen (an NSAID with near-complete inhibition of platelet function throughout its dosing interval), or another nonselective NSAIDs used in the development program (diclofenac, ibuprofen, and nabumetone)." | 2.41 | Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. ( Barr, E; Gertz, BJ; Konstam, MA; Reicin, A; Shapiro, D; Sperling, RS; Weir, MR, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.85) | 18.2507 |
| 2000's | 20 (76.92) | 29.6817 |
| 2010's | 3 (11.54) | 24.3611 |
| 2020's | 2 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Anwar, G | 1 |
| Chen, D | 1 |
| Chen, Q | 1 |
| Xia, C | 1 |
| Yan, J | 1 |
| Jordan, F | 1 |
| Quinn, TJ | 1 |
| McGuinness, B | 1 |
| Passmore, P | 1 |
| Kelly, JP | 1 |
| Tudur Smith, C | 1 |
| Murphy, K | 1 |
| Devane, D | 1 |
| Cao, LL | 1 |
| Guan, PP | 1 |
| Liang, YY | 1 |
| Huang, XS | 1 |
| Wang, P | 1 |
| Graham, DY | 1 |
| Jewell, NP | 1 |
| Chan, FK | 1 |
| Madigan, D | 1 |
| Sigelman, DW | 1 |
| Mayer, JW | 1 |
| Furberg, CD | 1 |
| Avorn, J | 1 |
| Devière, J | 1 |
| Scali, C | 1 |
| Giovannini, MG | 1 |
| Prosperi, C | 1 |
| Bellucci, A | 1 |
| Pepeu, G | 1 |
| Casamenti, F | 1 |
| Aisen, PS | 3 |
| Schafer, K | 1 |
| Grundman, M | 2 |
| Thomas, R | 1 |
| Thal, LJ | 3 |
| Schafer, KA | 1 |
| Pfeiffer, E | 1 |
| Sano, M | 1 |
| Davis, KL | 1 |
| Farlow, MR | 1 |
| Jin, S | 1 |
| Thomas, RG | 1 |
| Czap, A | 1 |
| Robertson, M | 1 |
| Weir, MR | 2 |
| Sperling, RS | 2 |
| Reicin, A | 2 |
| Gertz, BJ | 2 |
| Reines, SA | 1 |
| Block, GA | 1 |
| Morris, JC | 1 |
| Liu, G | 1 |
| Nessly, ML | 2 |
| Lines, CR | 2 |
| Norman, BA | 2 |
| Baranak, CC | 1 |
| Couzin, J | 1 |
| Lacomblez, L | 1 |
| Aizen, E | 1 |
| Kagan, G | 1 |
| Assy, B | 1 |
| Iobel, R | 1 |
| Bershadsky, Y | 1 |
| Gilhar, A | 1 |
| Visser, PJ | 1 |
| Scheltens, P | 1 |
| Verhey, FR | 1 |
| Jelic, V | 1 |
| Kivipelto, M | 1 |
| Winblad, B | 1 |
| Ciabattoni, G | 1 |
| Porreca, E | 1 |
| Di Febbo, C | 1 |
| Di Iorio, A | 1 |
| Paganelli, R | 1 |
| Bucciarelli, T | 1 |
| Pescara, L | 1 |
| Del Re, L | 1 |
| Giusti, C | 1 |
| Falco, A | 1 |
| Sau, A | 1 |
| Patrono, C | 1 |
| Davì, G | 1 |
| Ownby, RL | 1 |
| Ferris, SH | 1 |
| Assaid, C | 1 |
| Giuliani, MJ | 1 |
| Potter, WZ | 1 |
| Psaty, BM | 1 |
| Kronmal, RA | 1 |
| Pascucci, RA | 1 |
| Blain, H | 1 |
| Jouzeau, JY | 1 |
| Blain, A | 1 |
| Terlain, B | 1 |
| Tréchot, P | 1 |
| Touchon, J | 1 |
| Netter, P | 1 |
| Jeandel, C | 1 |
| Ferencik, M | 1 |
| Novak, M | 1 |
| Rovensky, J | 1 |
| Rybar, I | 1 |
| Konstam, MA | 1 |
| Shapiro, D | 1 |
| Barr, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter Trial of Rofecoxib and Naproxen in Alzheimer's Disease[NCT00004845] | Phase 2/Phase 3 | 0 participants | Interventional | Completed | |||
| A Multicenter, Randomized, Double Blind, Placebo Controlled, Parallel Group Study of the Efficacy and Safety of 9600 and 4800 mg/Day Piracetam Taken for 12 Months by Subjects Suffering From Mild Cognitive Impairment (MCI)[NCT00567060] | 676 participants (Actual) | Interventional | 2000-05-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 reviews available for rofecoxib and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Aspirin and other non-steroidal anti-inflammatory drugs for the prevention of dementia.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Alzheimer Disease; Anti-Inflammatory Age | 2020 |
Do selective cyclo-oxygenase inhibitors eliminate the adverse events associated with nonsteroidal anti-inflammatory drug therapy?
Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Hu | 2002 |
Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.
Topics: Alzheimer Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Blood | 2003 |
Clinical trials in mild cognitive impairment: lessons for the future.
Topics: Aged; Alzheimer Disease; Anti-Inflammatory Agents; Cholinesterase Inhibitors; Clinical Trials as Top | 2006 |
[Non-steroidal anti-inflammatory drugs with selectivity for cyclooxygenase-2 in Alzheimer's disease. Rationale and perspectives].
Topics: Adult; Age Factors; Aged; Alzheimer Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Brain | 2000 |
Alzheimer's disease, inflammation and non-steroidal anti-inflammatory drugs.
Topics: Alzheimer Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Brain; Celecoxib; Cyclooxygenas | 2001 |
Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib.
Topics: Aged; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascu | 2001 |
7 trials available for rofecoxib and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Cycloo | 2003 |
Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study.
Topics: Aged; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Apolipoprotein E4; Apolipoproteins | 2004 |
Effect of non-steroidal anti-inflammatory drugs on natural killer cell activity in patients with dementia.
Topics: Adult; Aged; Aged, 80 and over; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Cerebral | 2005 |
Do MCI criteria in drug trials accurately identify subjects with predementia Alzheimer's disease?
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Cholinesterase | 2005 |
Determinants of platelet activation in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Aspirin; Body Mass Index; C-Reacti | 2007 |
Rofecoxib in mild cognitive impairment.
Topics: Alzheimer Disease; Anti-Inflammatory Agents; Cognition Disorders; Cyclooxygenase 2 Inhibitors; Disea | 2006 |
Rofecoxib in patients with mild cognitive impairment: further analyses of data from a randomized, double-blind, trial.
Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Cognition Disorders; Cyclooxygenase 2 In | 2008 |
12 other studies available for rofecoxib and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Rofecoxib derivatives as NIR fluorescent probes for mitochondrial viscosity and in vivo imaging of Aβ plaques.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Biomarkers; Brain; Fluorescent Dyes; Mice; Optica | 2024 |
Cyclooxygenase-2 is Essential for Mediating the Effects of Calcium Ions on Stimulating Phosphorylation of Tau at the Sites of Ser 396 and Ser 404.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Animals; Blotting, Western; Calcium; Cyclooxygenase 2; C | 2019 |
Rofecoxib and clinically significant upper and lower gastrointestinal events revisited based on documents from recent litigation.
Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cyclooxygenase 2 | 2011 |
Under-reporting of cardiovascular events in the rofecoxib Alzheimer disease studies.
Topics: Adverse Drug Reaction Reporting Systems; Alzheimer Disease; Cardiovascular Diseases; Cyclooxygenase | 2012 |
The selective cyclooxygenase-2 inhibitor rofecoxib suppresses brain inflammation and protects cholinergic neurons from excitotoxic degeneration in vivo.
Topics: Alzheimer Disease; Animals; Astrocytes; Brain; Cell Death; Choline O-Acetyltransferase; Cholinergic | 2003 |
NSAIDs and hypertension.
Topics: Aged; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Double-Blind Metho | 2003 |
Pass the tablet please.
Topics: Aged; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Ginkgo biloba | 2003 |
Effect of NSAIDs on risk of Alzheimer's disease: confounding factors were not discussed.
Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Humans; Lactones; Naproxen; Randomized C | 2003 |
Clinical trials. Nail-biting time for trials of COX-2 drugs.
Topics: Alzheimer Disease; Anticarcinogenic Agents; Cardiovascular Diseases; Celecoxib; Controlled Clinical | 2004 |
[Inflammation, nonsteroidal anti-inflammatory drugs and Alzheimer disease].
Topics: Aged; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Cyclooxy | 2004 |
Reporting mortality findings in trials of rofecoxib for Alzheimer disease or cognitive impairment: a case study based on documents from rofecoxib litigation.
Topics: Alzheimer Disease; Clinical Trials as Topic; Clinical Trials Data Monitoring Committees; Cognition D | 2008 |
COX-2-specific inhibition: implications for clinical practice.
Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Blood Platelets; Celecoxib; Colorectal N | 1999 |